CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Elk Orthobiologics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Elk Orthobiologics Ltd
L 1 123 Camberwell Rd
Phone: +61 398119966p:+61 398119966 Hawthorn, VIC  3123  Australia Fax: +61 396633360f:+61 396633360
Business Summary
Elk OrthoBiologics Limited is an Australia-based biotechnology company. The Company's lead program, CTL102/CB1954, is a Gene Directed Enzyme Prodrug Therapy (GDEPT), where a short acting therapy removes the soft synovial-like tissue from around a loosened prosthetic implant, allowing the existing prosthesis to be re-cemented to the bone. GDEPT is a onetime treatment designed to destroy an unwanted tissue. The Company is developing a minimally invasive biologic therapy for repairing aseptically loosened hip and knee prosthetic implants. Phase I clinical trials of CTL102/CB1954 were completed for a range of cancers, including prostate cancer and liver cancer. The 12 subject clinical trial in elderly patients suffering from debilitating levels of aseptic loosening demonstrated that GDEPT therapy followed by cement injection is a safe and feasible alternative to revision surgery, particularly in patients who cannot undergo surgery.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20096/30/2009-----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Independent Non-Executive Chairman of the Board Wayne A.Millen
Chief Executive Officer, Managing Director, Executive Director Andrew M.Bray
Chief Financial Officer Malcolm J.Booth
4 additional Officers and Directors records available in full report.

Business Names
Business Name
BDV
Broadvector Limited

General Information
Fax Number: +61 396633360


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023